Blood Plasma Derivatives Market

ID: MRFR/Pharma/0817-HCR
80 Pages
Nidhi Mandole
Last Updated: July 20, 2026
ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ ์กฐ์‚ฌ ๋ณด๊ณ ์„œ โ€“ 2032๋…„๊นŒ์ง€ ์˜ˆ์ธก
Blood Plasma Derivatives Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)6.47%
2024 Market Size$ 43.3 Billion
2025 Market Size$ 46.6 Billion
2035 Market Size$ 86.67 Billion
Key Players
Grifols
CSL Behring
Takeda Pharmaceutical Company Limited
Octapharma
Kedrion S.p.A.
Bio Products Laboratory
Opportunities
  • Rising Demand for Immunoglobulins
  • Growing Awareness of Rare Diseases
  • Emerging Markets and Global Expansion
  1. 2.1 ์ •์˜
    1. 2.2 ์—ฐ๊ตฌ ๋ฒ”์œ„
      1. 2.2.1 ์—ฐ๊ตฌ ๋ชฉํ‘œ
      2. 2.2.2 ๊ฐ€์ •
      3. 2.2.3 ํ•œ๊ณ„ 3์žฅ ์—ฐ๊ตฌ ๋ฐฉ๋ฒ•๋ก 
    2. 3.1 ๊ฐœ์š”
    3. 3.2 1์ฐจ ์—ฐ๊ตฌ
    4. 3.3 2์ฐจ ์—ฐ๊ตฌ
    5. 3.4 ์‹œ์žฅ ๊ทœ๋ชจ ์ถ”์ • 4์žฅ ์‹œ์žฅ ์—ญํ•™
    6. 4.1 ์„ฑ์žฅ ๋™๋ ฅ
    7. 4.2 ์ œ์•ฝ
    8. 4.3 ๊ธฐํšŒ
    9. 4.4 ๊ณผ์ œ 4์žฅ
  2. 5 ์‹œ์žฅ ์š”์ธ ๋ถ„์„
    1. 5.1 ํฌํ„ฐ์˜ 5๊ฐ€์ง€ ํž˜ ๋ถ„์„
      1. 5.1.1 ๊ณต๊ธ‰์—…์ฒด์˜ ํ˜‘์ƒ๋ ฅ
      2. 5.1.2 ๊ตฌ๋งค์ž์˜ ํ˜‘์ƒ๋ ฅ
      3. 5.1.3 ์‹ ๊ทœ ์ง„์ž…์ž์˜ ์œ„ํ˜‘
      4. 5.1.4 ๋Œ€์ฒด์žฌ์˜ ์œ„ํ˜‘
      5. 5.1.5 ๊ฒฝ์Ÿ์˜ ๊ฐ•๋„
    2. 5.2 ๊ฐ€์น˜ ์‚ฌ์Šฌ ๋ถ„์„ 6์žฅ ์œ ํ˜•๋ณ„ ๊ธ€๋กœ๋ฒŒ ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ
    3. 6.1 ๊ฐœ์š”
    4. 6.2 ์ œ8์ธ์ž ๋†์ถ•๋ฌผ ์ง€์—ญ๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2024-2032 ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ๊ตญ๊ฐ€๋ณ„ ์˜ˆ์ธก, 2024-2032
    5. 6.3 ์ธ์ž IX ๋†์ถ•์•ก ์ง€์—ญ๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2024-2032 ๊ตญ๊ฐ€๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2024-2032
    6. 6.4 ์•Œ๋ถ€๋ฏผ ์ง€์—ญ๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2024-2032 ๊ตญ๊ฐ€๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2024-2032
    7. 6.5 ๋ฉด์—ญ๊ธ€๋กœ๋ถˆ๋ฆฐ ์ง€์—ญ๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2024-2032 ๊ตญ๊ฐ€๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2024-2032
    8. 6.6 ํ•ญํŠธ๋กฌ๋นˆ III ๋†์ถ•์•ก ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์ง€์—ญ๋ณ„ ์˜ˆ์ธก, 2024-2032 ๊ตญ๊ฐ€๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2024-2032
    9. 6.7 ์‹ ์„  ๋™๊ฒฐ ํ˜ˆ์žฅ(FFP) ์ง€์—ญ๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2024-2032 ๊ตญ๊ฐ€๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2024-2032 7์žฅ ์šฉ๋„๋ณ„ ๊ธ€๋กœ๋ฒŒ ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ
    10. 7.1 ๊ฐœ์š”
    11. 7.2 HIV ์ง€์—ญ๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2024-2032 ๊ตญ๊ฐ€๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2024-2032
    12. 7.3 ํ˜ˆ์šฐ๋ณ‘ A ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์ง€์—ญ๋ณ„ ์˜ˆ์ธก, 2024-2032 ๊ตญ๊ฐ€๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2024-2032
    13. 7.4 Bํ˜• ํ˜ˆ์šฐ๋ณ‘ ์ง€์—ญ๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2024-2032 ๊ตญ๊ฐ€๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2024-2032
    14. 7.5 Bํ˜• ๊ฐ„์—ผ ์ง€์—ญ๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2024-2032 ๊ตญ๊ฐ€๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2024-2032
    15. 7.6 Cํ˜• ๊ฐ„์—ผ ์ง€์—ญ๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2024-2032 ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ๊ตญ๊ฐ€๋ณ„ ์˜ˆ์ธก, 2024-2032
    16. 7.7 ์ถœํ˜ˆ ์žฅ์•  ์ง€์—ญ๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2024-2032 ๊ตญ๊ฐ€๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2024-2032
    17. 7.8 ์ €๊ฐ๋งˆ๊ธ€๋กœ๋ถˆ๋ฆฐํ˜ˆ์ฆ ์ง€์—ญ๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2024-2032 ๊ตญ๊ฐ€๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2024-2032
    18. 7.9 ๋ฉด์—ญ๊ฒฐํ• ์งˆํ™˜ ์ง€์—ญ๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2024-2032 ๊ตญ๊ฐ€๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2024-2032
    19. 7.10 ๊ธฐํƒ€ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์ง€์—ญ๋ณ„ ์˜ˆ์ธก, 2024-2032 ๊ตญ๊ฐ€๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2024-2032 ์ œ8์žฅ ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„ ๊ธ€๋กœ๋ฒŒ ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ
    20. 8.1 ๊ฐœ์š”
    21. 8.2 ๋ณ‘์› ๋ฐ ์ง„๋ฃŒ์†Œ ์ง€์—ญ๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2024-2032 ๊ตญ๊ฐ€๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2024-2032
    22. 8.3 ์ˆ˜ํ˜ˆ ์„ผํ„ฐ ์ง€์—ญ๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2024-2032 ๊ตญ๊ฐ€๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์˜ˆ์ธก, 2024-2032
    23. 8.4 ์ง„๋‹จ ์„ผํ„ฐ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์ง€์—ญ๋ณ„ ์ „๋ง, 2024-2032 ๊ตญ๊ฐ€๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์ „๋ง, 2024-2032
    24. 8.5 ๊ธฐํƒ€ ์ง€์—ญ๋ณ„ ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์ „๋ง, 2024-2032 ์‹œ์žฅ ์ถ”์ •์น˜ ๋ฐ ์ „๋ง ๊ตญ๊ฐ€๋ณ„ ์ „๋ง, 2024-2032 ์ œ10์žฅ. ์ง€์—ญ๋ณ„ ์„ธ๊ณ„ ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ
    25. 10.1 ๊ฐœ์š”
    26. 10.2 ์•„๋ฉ”๋ฆฌ์นด
      1. 10.2.1 ๋ถ๋ฏธ
        1. 10.2.1.1 ๋ฏธ๊ตญ
        2. 10.2.1.2 ์บ๋‚˜๋‹ค
      2. 10.2.2 ๋ผํ‹ด ์•„๋ฉ”๋ฆฌ์นด
    27. 10.3 ์œ ๋Ÿฝ
      1. 10.3.1 ์„œ์œ ๋Ÿฝ
        1. 10.3.1.1 ๋…์ผ
        2. 10.3.1.2 ํ”„๋ž‘์Šค
        3. 10.3.1.3 ์ดํƒˆ๋ฆฌ์•„
        4. 10.3.1.4 ์ŠคํŽ˜์ธ
        5. 10.3.1.5 ์˜๊ตญ
        6. 10.3.1.6 ๊ธฐํƒ€ ์„œ์œ ๋Ÿฝ
      2. 10.3.2 ๋™์œ ๋Ÿฝ
    28. 10.4 ์•„์‹œ์•„ ํƒœํ‰์–‘
      1. 10.4.1 ์ผ๋ณธ
      2. 10.4.2 ์ค‘๊ตญ
      3. 10.4.3 ์ธ๋„
      4. 10.4.4 ํ˜ธ์ฃผ
      5. 10.4.5 ํ•œ๊ตญ
      6. 10.4.6 ๊ธฐํƒ€ ์•„์‹œ์•„ ํƒœํ‰์–‘
    29. 10.5 ์ค‘๋™ ๋ฐ ์•„ํ”„๋ฆฌ์นด
      1. 10.5.1 ์ค‘๋™
      2. 10.5.2 ์•„ํ”„๋ฆฌ์นด ์ œ11์žฅ ํšŒ์‚ฌ ํ˜„ํ™ฉ
    30. 11.1 ๊ฐœ์š”
    31. 11.2 ๊ฒฝ์Ÿ ๋ถ„์„ 12์žฅ ํšŒ์‚ฌ ํ”„๋กœํ•„
    32. 12.1 Baxter BioScience
      1. 12.1.1 ํšŒ์‚ฌ ๊ฐœ์š”
      2. 12.1.2 ์ œํ’ˆ ์œ ํ˜• ๊ฐœ์š”
      3. 12.1.3 ์žฌ๋ฌด ๊ฐœ์š”
      4. 12.1.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 12.1.5 SWOT ๋ถ„์„
    33. 12.2 Grifols S.A.
      1. 12.2.1 ํšŒ์‚ฌ ๊ฐœ์š”
      2. 12.2.2 ์ œํ’ˆ ์œ ํ˜• ๊ฐœ์š”
      3. 12.2.3 ์žฌ๋ฌด ๊ฐœ์š”
      4. 12.2.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 12.2.5 SWOT ๋ถ„์„
    34. 12.3 CSL Behring
      1. 12.3.1 ํšŒ์‚ฌ ๊ฐœ์š”
      2. 12.3.2 ์ œํ’ˆ ์œ ํ˜• ๊ฐœ์š”
      3. 12.3.3 ์žฌ๋ฌด ๊ฐœ์š”
      4. 12.3.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 12.3.5 SWOT ๋ถ„์„
    35. 12.4 ViroPharma, Inc.
      1. 12.4.1 ํšŒ์‚ฌ ๊ฐœ์š”
      2. 12.4.2 ์ œํ’ˆ ์œ ํ˜• ๊ฐœ์š”
      3. 12.4.3 ์žฌ๋ฌด ๊ฐœ์š”
      4. 12.4.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 12.4.5 SWOT ๋ถ„์„
    36. 12.5 Talecris Biotherapeutics, Inc.
      1. 12.5.1 ํšŒ์‚ฌ ๊ฐœ์š”
      2. 12.5.2 ์ œํ’ˆ ์œ ํ˜• ๊ฐœ์š”
      3. 12.5.3 ์žฌ๋ฌด ๊ฐœ์š”
      4. 12.5.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 12.5.5 SWOT ๋ถ„์„
    37. 12.6 Octapharma
      1. 12.6.1 ํšŒ์‚ฌ ๊ฐœ์š”
      2. 12.6.2 ์ œํ’ˆ ์œ ํ˜• ๊ฐœ์š”
      3. 12.6.3 ์žฌ๋ฌด ๊ฐœ์š”
      4. 12.6.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 12.6.5 SWOT ๋ถ„์„
    38. 12.7 Fusion Healthcare
      1. 12.7.1 ๊ฐœ์š”
      2. 12.7.2 ์ œํ’ˆ ์œ ํ˜• ๊ฐœ์š”
      3. 12.7.3 ์žฌ๋ฌด ๊ฐœ์š”
      4. 12.7.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 12.7.5 SWOT ๋ถ„์„
    39. 12.8 SKํ”Œ๋ผ์ฆˆ๋งˆ(์ฃผ)
      1. 12.8.1 ๊ฐœ์š”
      2. 12.8.2 ์ œํ’ˆ ์œ ํ˜• ๊ฐœ์š”
      3. 12.8.3 ์žฌ๋ฌด ๊ฐœ์š”
      4. 12.8.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 12.8.5 SWOT ๋ถ„์„
    40. 12.9 Biotest AG
      1. 12.9.1 ๊ฐœ์š”
      2. 12.9.2 ์ œํ’ˆ ์œ ํ˜• ๊ฐœ์š”
      3. 12.9.3 ์žฌ๋ฌด ๊ฐœ์š”
      4. 12.9.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 12.9.5 SWOT ๋ถ„์„
    41. 12.10 ๋…น์‹ญ์ž(์ฃผ)
      1. 12.10.1 ๊ฐœ์š”
      2. 12.10.2 ์ œํ’ˆ ์œ ํ˜• ๊ฐœ์š”
      3. 12.10.3 ์žฌ๋ฌด ๊ฐœ์š”
      4. 12.10.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 12.10.5 SWOT ๋ถ„์„
    42. 12.11 Shire Plc
      1. 12.11.1 ๊ฐœ์š”
      2. 12.11.2 ์ œํ’ˆ ์œ ํ˜• ๊ฐœ์š”
      3. 12.11.3 ์žฌ๋ฌด ๊ฐœ์š”
      4. 12.11.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 12.11.5 SWOT ๋ถ„์„
    43. 12.13 ๊ธฐํƒ€ 13์žฅ ๋ถ€๋ก
    44. 13.1 ์ฐธ๊ณ ๋ฌธํ—Œ
    45. 13.2 ๊ด€๋ จ ๋ณด๊ณ ์„œ ํ‘œ ๋ชฉ๋ก ํ‘œ 1 ๊ธ€๋กœ๋ฒŒ ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ ๊ฐœ์š”, 2024-2032 ํ‘œ 2 ๊ธ€๋กœ๋ฒŒ ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ ์ถ”์ • ๋ฐ ์˜ˆ์ธก, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) ํ‘œ 3 ๊ธ€๋กœ๋ฒŒ ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, ์œ ํ˜•๋ณ„, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) ํ‘œ 4 ๊ธ€๋กœ๋ฒŒ ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, ์‘์šฉ ๋ถ„์•ผ๋ณ„, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) ํ‘œ 5 ๊ธ€๋กœ๋ฒŒ ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) ํ‘œ 6 ๊ธ€๋กœ๋ฒŒ ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, ์ง€์—ญ๋ณ„, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) ํ‘œ 7 ๋ถ๋ฏธ: ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, ์œ ํ˜•๋ณ„, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) ํ‘œ 8 ๋ถ๋ฏธ ๋ฏธ๊ตญ: ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, ์‘์šฉ ๋ถ„์•ผ๋ณ„, 2024-2032๋…„(USD) ํ‘œ 9 ๋ถ๋ฏธ: ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„, 2024-2032๋…„(USD) ํ‘œ 10 ๋ฏธ๊ตญ: ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, ์œ ํ˜•๋ณ„, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) ํ‘œ 11 ๋ฏธ๊ตญ: ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, ์‘์šฉ ๋ถ„์•ผ๋ณ„, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) ํ‘œ 12 ๋ฏธ๊ตญ: ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) ํ‘œ 13 ์บ๋‚˜๋‹ค: ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, ์œ ํ˜•๋ณ„, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) ํ‘œ 14 ์บ๋‚˜๋‹ค: ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, ์šฉ๋„๋ณ„, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) ํ‘œ 15 ์บ๋‚˜๋‹ค: ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) ํ‘œ 16 ๋ผํ‹ด ์•„๋ฉ”๋ฆฌ์นด: ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, ์œ ํ˜•๋ณ„, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) ํ‘œ 17 ๋ผํ‹ด ์•„๋ฉ”๋ฆฌ์นด: ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, ์šฉ๋„๋ณ„, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) ํ‘œ 18 ๋ผํ‹ด ์•„๋ฉ”๋ฆฌ์นด: ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) ํ‘œ 19 ์œ ๋Ÿฝ: ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, ์œ ํ˜•๋ณ„, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) 10์–ต ๋‹ฌ๋Ÿฌ) ํ‘œ 20 ์œ ๋Ÿฝ: ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, ์šฉ๋„๋ณ„, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) ํ‘œ 21 ์œ ๋Ÿฝ: ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) ํ‘œ 22 ์„œ์œ ๋Ÿฝ: ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, ์œ ํ˜•๋ณ„, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) ํ‘œ 23 ์„œ์œ ๋Ÿฝ: ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, ์šฉ๋„๋ณ„, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) ํ‘œ 24 ์„œ์œ ๋Ÿฝ: ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) 10์–ต ๋‹ฌ๋Ÿฌ) ํ‘œ 25 ๋™์œ ๋Ÿฝ: ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, ์œ ํ˜•๋ณ„, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) ํ‘œ 26 ๋™์œ ๋Ÿฝ: ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, ์‘์šฉ ๋ถ„์•ผ๋ณ„, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) ํ‘œ 27 ๋™์œ ๋Ÿฝ: ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„ ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) ํ‘œ 28 ์•„์‹œ์•„ ํƒœํ‰์–‘: ์œ ํ˜•๋ณ„ ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) ํ‘œ 29 ์•„์‹œ์•„ ํƒœํ‰์–‘: ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, ์‘์šฉ ๋ถ„์•ผ๋ณ„, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) ํ‘œ 30 ์•„์‹œ์•„ ํƒœํ‰์–‘: ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) ํ‘œ 31 ์ค‘๋™ ๋ฐ ์•„ํ”„๋ฆฌ์นด: ์œ ํ˜•๋ณ„ ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) ํ‘œ 32 ์ค‘๋™ ๋ฐ ์•„ํ”„๋ฆฌ์นด: ์‘์šฉ ๋ถ„์•ผ๋ณ„ ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, 2024-2032(10์–ต ๋‹ฌ๋Ÿฌ) ํ‘œ 33 ์ค‘๋™ ๋ฐ ์•„ํ”„๋ฆฌ์นด: ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„ ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, 2024-2032(10์–ต ๋‹ฌ๋Ÿฌ) ? ๊ทธ๋ฆผ ๋ชฉ๋ก ๊ทธ๋ฆผ 1 ์—ฐ๊ตฌ ๊ณผ์ • ๊ทธ๋ฆผ 2 ๊ธ€๋กœ๋ฒŒ ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ์˜ ์‹œ์žฅ ๊ตฌ์กฐ ๊ทธ๋ฆผ 3 ๊ธ€๋กœ๋ฒŒ ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ์˜ ์‹œ์žฅ ์—ญํ•™ ๊ทธ๋ฆผ 5 ์œ ํ˜•๋ณ„ ๊ธ€๋กœ๋ฒŒ ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) ๊ทธ๋ฆผ 6 ์šฉ๋„๋ณ„ ๊ธ€๋กœ๋ฒŒ ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, 2024-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) ๊ทธ๋ฆผ 7 ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„ ๊ธ€๋กœ๋ฒŒ ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, 2024-2032๋…„ (10์–ต ๋‹ฌ๋Ÿฌ) ๊ทธ๋ฆผ 8 ์ง€์—ญ๋ณ„ ๊ธ€๋กœ๋ฒŒ ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ, 2024-2032๋…„ (10์–ต ๋‹ฌ๋Ÿฌ) ๊ทธ๋ฆผ 9 ๋ถ๋ฏธ: ๊ตญ๊ฐ€๋ณ„ ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ ์ ์œ ์œจ, 2023๋…„ (%) ๊ทธ๋ฆผ 10 ์œ ๋Ÿฝ: ์ง€์—ญ๋ณ„ ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ ์ ์œ ์œจ, 2023๋…„ (%) ๊ทธ๋ฆผ 11 ์„œ์œ ๋Ÿฝ: ๊ตญ๊ฐ€๋ณ„ ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ ์ ์œ ์œจ, 2023๋…„ (%) ๊ทธ๋ฆผ 12 ์•„์‹œ์•„ ํƒœํ‰์–‘: ๊ตญ๊ฐ€๋ณ„ ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ ์ ์œ ์œจ, 2023๋…„ (%) ๊ทธ๋ฆผ 13 ์ค‘๋™ ๋ฐ ์•„ํ”„๋ฆฌ์นด: ๊ตญ๊ฐ€๋ณ„ ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ ์ ์œ ์œจ, 2023๋…„ (%) ๊ทธ๋ฆผ 14 ๊ธ€๋กœ๋ฒŒ ํ˜ˆ์žฅ ํŒŒ์ƒ๋ฌผ ์‹œ์žฅ: ๊ธฐ์—… ์ ์œ ์œจ ๋ถ„์„, 2023๋…„ (%) ๊ทธ๋ฆผ 15 Baxter BioScience: ์ฃผ์š” ์žฌ๋ฌด ๊ฐœ์š” ๊ทธ๋ฆผ 16 Baxter BioScience: ๋ถ€๋ฌธ๋ณ„ ๋งค์ถœ ๊ทธ๋ฆผ 17 Baxter BioScience: ์ง€์—ญ๋ณ„ ๋งค์ถœ ๊ทธ๋ฆผ 18 Grifols S.A.: ์ฃผ์š” ์žฌ๋ฌด ๊ฐœ์š” ๊ทธ๋ฆผ 19 Grifols S.A.: ๋ถ€๋ฌธ๋ณ„ ๋งค์ถœ ๊ทธ๋ฆผ 20 Grifols S.A.: ์ง€์—ญ๋ณ„ ๋งค์ถœ ๊ทธ๋ฆผ 21 CSL Behring: ์ฃผ์š” ์žฌ๋ฌด ๊ฐœ์š” ๊ทธ๋ฆผ 22 CSL Behring: ๋ถ€๋ฌธ๋ณ„ ๋งค์ถœ ๊ทธ๋ฆผ 23 CSL Behring: ์ง€์—ญ๋ณ„ ๋งค์ถœ ๊ทธ๋ฆผ 24 ViroPharma, Inc.: ์ฃผ์š” ์žฌ๋ฌด ๊ฐœ์š” ๊ทธ๋ฆผ 25 ViroPharma, Inc.: ๋ถ€๋ฌธ๋ณ„ ๋งค์ถœ ๊ทธ๋ฆผ 26 ViroPharma, Inc.: ์ง€์—ญ๋ณ„ ๋งค์ถœ ๊ทธ๋ฆผ 27 Talecris Biotherapeutics, Inc.: ์ฃผ์š” ์žฌ๋ฌด ๊ฐœ์š” ๊ทธ๋ฆผ 28 Talecris Biotherapeutics, Inc.: ๋ถ€๋ฌธ๋ณ„ ๋งค์ถœ ๊ทธ๋ฆผ 29 Talecris Biotherapeutics, Inc.: ์ง€์—ญ๋ณ„ ๋งค์ถœ ๊ทธ๋ฆผ 30 Octapharma: ์ฃผ์š” ์žฌ๋ฌด ๊ฐœ์š” ๊ทธ๋ฆผ 31 Octapharma: ๋ถ€๋ฌธ๋ณ„ ๋งค์ถœ ๊ทธ๋ฆผ 32 Octapharma: ์ง€์—ญ๋ณ„ ๋งค์ถœ ๊ทธ๋ฆผ 33 Fusion Healthcare: ์ฃผ์š” ์žฌ๋ฌด ๊ฐœ์š” ๊ทธ๋ฆผ 34 Fusion Healthcare: ๋ถ€๋ฌธ๋ณ„ ๋งค์ถœ ๊ทธ๋ฆผ 35 Fusion Healthcare: ์ง€์—ญ๋ณ„ ๋งค์ถœ ๊ทธ๋ฆผ 36 SK Plasma Co., Ltd.: ์ฃผ์š” ์žฌ๋ฌด ๊ฐœ์š” ๊ทธ๋ฆผ 37 SK Plasma Co., Ltd.: ๋ถ€๋ฌธ๋ณ„ ๋งค์ถœ ๊ทธ๋ฆผ 38 SK Plasma Co., Ltd.: ์ง€์—ญ๋ณ„ ๋งค์ถœ ๊ทธ๋ฆผ 39 Biotest AG: ์ฃผ์š” ์žฌ๋ฌด ๊ฐœ์š” ๊ทธ๋ฆผ 40 Biotest AG: ๋ถ€๋ฌธ๋ณ„ ๋งค์ถœ ๊ทธ๋ฆผ 41 Biotest AG: ์ง€์—ญ๋ณ„ ๋งค์ถœ ๊ทธ๋ฆผ 42 Green Cross Corporation: ์ฃผ์š” ์žฌ๋ฌด ๊ฐœ์š” ๊ทธ๋ฆผ 43 Green Cross Corporation: ๋ถ€๋ฌธ๋ณ„ ๋งค์ถœ ๊ทธ๋ฆผ 44 Green Cross Corporation: ์ง€์—ญ๋ณ„ ๋งค์ถœ ๊ทธ๋ฆผ 45 Shire Plc: ์ฃผ์š” ์žฌ๋ฌด ๊ฐœ์š” ๊ทธ๋ฆผ 46 Shire Plc: ๋ถ€๋ฌธ๋ณ„ ๋งค์ถœ ๊ทธ๋ฆผ 47 Shire Plc: ์ง€์—ญ๋ณ„ ๋งค์ถœ
Case Study Cover Image
์‚ฌ๋ก€ ์—ฐ๊ตฌ

Aerospace & Defense

Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.